Jonathan R Brody

List of Publications by Year
in descending order

Version: 2024-02-01

66 papers	3,141 citations	201674 27 h-index	161849 54 g-index
67 all docs	67 docs citations	67 times ranked	5735 citing authors

#	Article	IF	Citations
1	Psychosocial distress is dynamic across the spectrum of cancer care and requires longitudinal screening for patient-centered care. Supportive Care in Cancer, 2022, 30, 4255-4264.	2.2	9
2	Disparities in pancreatic cancer care and research in Native Americans: Righting a history of wrongs. Cancer, 2022, 128, 1560-1567.	4.1	2
3	HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Cancers, 2022, 14, 1848.	3.7	4
4	The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Molecular and Cellular Biology, 2022, 42, .	2.3	6
5	Disparities in Electronic Screening for Cancer-Related Psychosocial Distress May Promote Systemic Barriers to Quality Oncologic Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 765-773.e4.	4.9	5
6	Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phaseâ€“Dependent Manner. Molecular Cancer Research, 2021, 19, 207-214.	3.4	6
7	AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Molecular Cancer Research, 2021, 19, 565-572.	3.4	5
8	Gemcitabine-loaded microbubble system for ultrasound imaging and therapy. Acta Biomaterialia, 2021, 130, 385-394.	8.3	21
9	The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Molecular Cancer Therapeutics, 2021, 20, 2166-2176.	4.1	19
10	Envisioning the future of precision oncology trials. Nature Cancer, 2021, 2, 9-11.	13.2	19
11	Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties. Molecular Cancer Therapeutics, 2021, 20, 553-563.	4.1	7
12	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5092-5101.	7.0	28
13	Targeting homologous recombination addicted tumors: challenges and opportunities. Annals of Pancreatic Cancer, 2020, 3, 6-6.	1.2	3
14	A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surgical Oncology, 2020, 33, 118-125.	1.6	4
15	Ultra-fast conductive media for RNA electrophoretic mobility shift assays. BioTechniques, 2020, 68, 101-105.	1.8	1
16	Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Journal of the American College of Surgeons, 2020, 230, 659-667.	0.5	6
17	Understanding and targeting the diseaseâ€related RNA binding protein human antigen R (HuR). Wiley Interdisciplinary Reviews RNA, 2020, 11, e1581.	6.4	119
18	Rules for scientific progress while living with the COVID-19 Pandemic: from â€˜benchsideâ€™ to â€˜fireside.â€™. Cancer Biology and Therapy, 2020, 21, 581-582.	3.4	1

#	Article	IF	Citations
19	RNA binding protein HuR regulates extracellular matrix gene expression and pH homeostasis independent of controlling HIF-1Î± signaling in nucleus pulposus cells. Matrix Biology, 2019, 77, 23-40.	3.6	32
20	Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Molecular Cancer Research, 2019, 17, 2029-2041.	3.4	37
21	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Research, 2019, 79, 4491-4502.	0.9	27
22	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Molecular Cancer Therapeutics, 2019, 18, 1899-1908.	4.1	52
23	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Molecular Cancer Research, 2019, 17, 1815-1827.	3.4	40
24	A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Pancreatic Cancer, 2019, 5, 12-21.	0.9	2
25	Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets. Methods in Molecular Biology, 2019, 1882, 239-252.	0.9	29
26	Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clinical Cancer Research, 2019, 25, 724-734.	7.0	48
27	RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Molecular Cancer Research, 2019, 17, 508-520.	3.4	17
28	STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Clinical Cancer Research, 2018, 24, 1917-1931.	7.0	48
29	Complex HuR function in pancreatic cancer cells. Wiley Interdisciplinary Reviews RNA, 2018, 9, e1469.	6.4	29
30	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons, 2018, 226, 596-603.	0.5	5
31	Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biology and Therapy, 2018, 19, 249-253.	3.4	18
32	Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Molecular and Cellular Biology, 2018, 38, .	2.3	22
33	Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer. Annals of Surgery, 2018, 267, 364-369.	4.2	26
34	Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry. Journal of Pancreatic Cancer, 2018, 4, 17-24.	0.9	0
35	Metabolic Dependencies in Pancreatic Cancer. Frontiers in Oncology, 2018, 8, 617.	2.8	60
36	Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. Journal of Pancreatic Cancer, 2018, 4, 81-87.	0.9	4

#	Article	IF	Citations
37	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
38	CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Molecular Cancer Research, 2017, 15, 696-707.	3.4	39
39	Alterations of type II classical cadherin, cadherinâ€10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 427-435.	2.8	8
40	Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Research, 2017, 77, 5011-5025.	0.9	59
41	Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Research, 2017, 77, 4460-4471.	0.9	87
42	Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget, 2017, 8, 37923-37934.	1.8	23
43	Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget, 2016, 7, 74043-74058.	1.8	86
44	HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Molecular Cancer Research, 2016, 14, 599-611.	3.4	45
45	WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Scientific Reports, 2016, 6, 33323.	3.3	33
46	Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth. Cancer Research, 2016, 76, 1549-1559.	0.9	74
47	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology, 2016, 150, 48-63.	1.3	90
48	Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget, 2016, 7, 21812-21824.	1.8	7
49	Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?. Discovery Medicine, 2016, 21, 117-23.	0.5	27
50	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	7.1	376
51	Novel Targets in Pancreatic Cancer Research. Seminars in Oncology, 2015, 42, 177-187.	2.2	19
52	MUC1 Promoterâ€“Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	3.4	18
53	Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget, 2015, 6, 27312-27331.	1.8	47
54	dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biology and Therapy, 2014, 15, 688-698.	3.4	39

#	Article	IF	Citations
55	PARP Inhibitors for Chemopreventionâ€"Letter. Cancer Prevention Research, 2014, 7, 1170-1171.	1.5	5
56	Fusing Transcriptomics to Progressive Prostate Cancer. American Journal of Pathology, 2014, 184, 2608-2610.	3.8	0
57	Structural Implications for Selective Targeting of PARPs. Frontiers in Oncology, 2013, 3, 301.	2.8	121
58	The Past, Present, and Future of Biomarkers: A Need for Molecular Beacons for the Clinical Management of Pancreatic Cancer. Advances in Surgery, 2011, 45, 301-321.	1.3	22
59	HuR's role in gemcitabine efficacy: an exception or opportunity?. Wiley Interdisciplinary Reviews RNA, 2011, 2, 435-444.	6.4	15
60	HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients. Annals of Surgery, 2010, 252, 499-506.	4.2	84
61	CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers. Cancer Biology and Therapy, 2010, 10, 615-616.	3.4	1
62	pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs. PLoS ONE, 2010, 5, e15455.	2.5	42
63	Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle, 2009, 8, 1930-1934.	2.6	152
64	Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Modern Pathology, 2009, 22, 651-659.	5.5	83
65	Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biology and Therapy, 2008, 7, 1496-1506.	3.4	82
66	Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Modern Pathology, 2007, 20, 1238-1244.	5.5	19